Advertisement

Neuroleptic Malignant Syndrome

  • Stanley N. CaroffEmail author
  • Stephan C. Mann
  • Kenneth A. Sullivan
  • E. Cabrina Campbell
Chapter
Part of the Current Clinical Neurology book series (CCNEU)

Abstract

Since the original description of neuroleptic malignant syndrome (NMS) over 50 years ago, a wealth of clinical data has accumulated on the clinical features, treatment, and pathogenesis of this uncommon but potentially lethal drug reaction. As a result, substantial progress has been achieved in reducing the incidence and mortality of NMS by increasing acceptance, awareness, and recognition of the disorder, more conservative prescribing practices, reduction of proposed risk factors, and development and marketing of newer antipsychotics with less liability for extrapyramidal side effects. Early diagnosis, cessation of neuroleptic medications, prompt medical intervention, and consideration of specific remedies comprise the mainstay of management. Nevertheless, vigilance must be maintained, as NMS remains obscure to most clinicians in practice. It is therefore essential for all physicians to become familiar with the diagnosis and treatment of this serious and treatable drug reaction.

Keywords

Dopamine Agonist Neuroleptic Malignant Syndrome Malignant Hyperthermia Malignant Hyperthermia Neuroleptic Medication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Delay J, Pichot P, Lemperiere T, Elissade B, Peigne F. Un neuroleptique majeur non-phenothiazine et non-reserpinique, l’haloperidol, dans le traitement des psychoses. Ann Med Psychol. 1960;118:145–52.Google Scholar
  2. 2.
    Itoh H, Ohtsuka N, Ogita K, Yagi G, Miura S, Koga Y. Malignant neuroleptic syndrome—its present status in Japan and clinical problems. Folia Psychiatr Neurol Jpn. 1977;31:565–76.Google Scholar
  3. 3.
    Bourgeois M, Tignol J, Henry P. Syndrome malin et morts subite au cours des traitements par neuroleptiques simple and retard. Ann Med Psychol. 1971;2:729–46.Google Scholar
  4. 4.
    Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry. 1980;41:79–83.PubMedGoogle Scholar
  5. 5.
    Meltzer HY. Rigidity, hyperpyrexia and coma following fluphenazine enanthate. Psychopharmacologia. 1973;29:337–46.PubMedCrossRefGoogle Scholar
  6. 6.
    Weinberger DR, Kelly MJ. Catatonia and malignant syndrome: a possible complication of neuroleptic administration. J Nerv Ment Dis. 1977;165:263–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77:185–202.PubMedGoogle Scholar
  8. 8.
    Caroff SN. Neuroleptic malignant syndrome. In: Mann SC, Caroff SN, Keck Jr PE, Lazarus A, editors. Neuroleptic malignant syndrome and related conditions. 2nd ed. Washington, D.C.: American Psychiatric Press, Inc.; 2003. p. 1–44.Google Scholar
  9. 9.
    Strawn JR, Keck Jr PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164:870–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Kinross-Wright VJ. Trifluoperazine and schizophrenia. In: Brill H, editor. Trifluoperazine: clinical and pharmacologic aspects. Philadelphia: Lea and Febiger; 1958. p. 62–70.Google Scholar
  11. 11.
    Stubner S, Rustenbeck E, Grohmann R, et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry. 2004;37 Suppl 1:S54–64.PubMedGoogle Scholar
  12. 12.
    Spivak B, Maline DI, Kozyrev VN, et al. Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow. Eur Psychiatry. 2000;15:330–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Keck Jr PE, Pope Jr HG, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome: a case-control study. Arch Gen Psychiatry. 1989;46:914–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Berardi D, Amore M, Keck Jr PE, Troia M, Dell’Atti M. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry. 1998;44:748–54.PubMedCrossRefGoogle Scholar
  15. 15.
    Caroff SN, Rosenberg H, Mann SC, Campbell EC, Gliatto MF. Neuroleptic malignant syndrome in the perioperative setting. Am J Anesthesiol. 2001;28:387–93.Google Scholar
  16. 16.
    White DA, Robins AH. Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry. 1991;158:419–21.PubMedCrossRefGoogle Scholar
  17. 17.
    Caroff SN, Mann SC, McCarthy M, Naser J, Rynn M, Morrison M. Acute infectious encephalitis complicated by neuroleptic malignant syndrome. J Clin Psychopharmacol. 1998;18:349–51.PubMedCrossRefGoogle Scholar
  18. 18.
    Rosebush PI, Mazurek MF. Serum iron and neuroleptic malignant syndrome. Lancet. 1991;338:149–51.PubMedCrossRefGoogle Scholar
  19. 19.
    Caroff SN, Mann SC. Neuroleptic malignant syndrome. Psychopharmacol Bull. 1988;24:25–9.PubMedGoogle Scholar
  20. 20.
    Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65:464–70.PubMedCrossRefGoogle Scholar
  21. 21.
    Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008;42:1290–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Mann SC, Caroff SN, Fricchione G, Campbell EC. Central dopamine hypoactivity and the pathogenesis of neuroleptic malignant syndrome. Psychiatr Ann. 2000;30:363–74.Google Scholar
  23. 23.
    Rosenberg MR, Green M. Neuroleptic malignant syndrome: review of response to therapy. Arch Intern Med. 1989;149:1927–31.PubMedCrossRefGoogle Scholar
  24. 24.
    Sakkas P, Davis JM, Janicak PG, Wang ZY. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull. 1991;27:381–4.PubMedGoogle Scholar
  25. 25.
    Davis JM, Caroff SN, Mann SC. Treatment of neuroleptic malignant syndrome. Psychiatr Ann. 2000;30:325–31.Google Scholar
  26. 26.
    Ueda M, Hamamoto M, Nagayama H, Okubo S, Amemiya S, Katayama Y. Biochemical alterations during medication withdrawal in Parkinson’s disease with and without neuroleptic malignant-like syndrome. J Neurol Neurosurg Psychiatry. 2001;71:111–3.PubMedCrossRefGoogle Scholar
  27. 27.
    Nisijima K, Ishiguro T. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiatr Res. 1995;29:233–44.PubMedCrossRefGoogle Scholar
  28. 28.
    Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. 1999;156:169–80.PubMedGoogle Scholar
  29. 29.
    Kornhuber J, Weller M, Riederer P. Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm. 1993;6:63–72.CrossRefGoogle Scholar
  30. 30.
    Portel L, Hilbert G, Gruson D, Favier JC, Gbikpi-Benissan G, Cardinaud JP. Malignant hyperthermia and neuroleptic malignant syndrome in a patient during treatment for acute asthma. Acta Anaesthesiol Scand. 1999;43:107–10.PubMedCrossRefGoogle Scholar
  31. 31.
    Sato T, Hara T, Takeichi M. A case of neuroleptic malignant syndrome with a history of general anesthesia. Hum Psychopharmacol. 1992;7:351–3.CrossRefGoogle Scholar
  32. 32.
    Caroff SN, Mann SC, Sullivan KA, Macfadden W. Drug-induced hypermetabolic syndromes. In: Ohnishi ST, Ohnishi T, editors. Malignant hyperthermia. Boca Raton, Florida: CRC Press, Inc.; 1994. p. 118–32.Google Scholar
  33. 33.
    Velamoor VR, Norman RM, Caroff SN, Mann SC, Sullivan KA, Antelo RE. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 1994;182:168–73.PubMedCrossRefGoogle Scholar
  34. 34.
    Sachdev PS. A rating scale for neuroleptic malignant syndrome. Psychiatry Res. 2005;135:249–56.PubMedCrossRefGoogle Scholar
  35. 35.
    American Psychiatric Association. Neuroleptic malignant syndrome. In: American Psychiatric Association, editor. Diagnostic and statistical manual of mental disorders. Washington, D.C: American Psychiatric Press, Inc; 1994. p. 739–42.Google Scholar
  36. 36.
    Gurrera RJ, Chang SS, Romero JA. A comparison of diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry. 1992;53:56–62.PubMedGoogle Scholar
  37. 37.
    Gurrera RJ, Caroff SN, Cohen A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011;72(9):1222–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Caroff SN, Mann SC, Keck Jr PE, Francis A. Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol. 2000;20:257–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Caroff SN, Mann SC, Gliatto MF, Sullivan KA, Campbell EC. Psychiatric manifestations of acute viral encephalitis. Psychiatr Ann. 2001;31:193–204.Google Scholar
  40. 40.
    Kayser MS, Kohler CG, Dalmau J. Psychiatric manifestations of paraneoplastic disorders. Am J Psychiatry. 2010;167:1039–50.PubMedCrossRefGoogle Scholar
  41. 41.
    Mann SC, Caroff SN, Bleier HR, Welz WK, Kling MA, Hayashida M. Lethal catatonia. Am J Psychiatry. 1986;143:1374–81.PubMedGoogle Scholar
  42. 42.
    Fricchione G, Mann SC, Caroff SN. Catatonia, lethal catatonia and neuroleptic malignant syndrome. Psychiatr Ann. 2000;30:347–55.Google Scholar
  43. 43.
    Mann SC, Boger WP. Psychotropic drugs, summer heat and humidity, and hyperpyrexia: a danger restated. Am J Psychiatry. 1978;135:1097–100.PubMedGoogle Scholar
  44. 44.
    Keck Jr PE, Arnold LM. The serotonin syndrome. Psychiatr Ann. 2000;30:333–43.Google Scholar
  45. 45.
    Woodbury MM, Woodbury MA. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry. 1992;31:1161–4.PubMedCrossRefGoogle Scholar
  46. 46.
    Rodriguez ME, Luquin MR, Lera G, Delgado G, Salazar JM, Obeso JA. Neuroleptic malignant syndrome treated with subcutaneous lisuride infusion. Mov Disord. 1990;5:170–2.PubMedCrossRefGoogle Scholar
  47. 47.
    Yamawaki S, Yano E, Uchitomi Y. Analysis of 497 cases of neuroleptic malignant syndrome in Japan. Hiroshima J Anesth. 1990;26:35–44.Google Scholar
  48. 48.
    Tsutsumi Y, Yamamoto K, Matsuura S, Hata S, Sakai M, Shirakura K. The treatment of neuroleptic malignant syndrome using dantrolene sodium. Psychiatry Clin Neurosci. 1998;52:433–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Stanley N. Caroff
    • 1
    Email author
  • Stephan C. Mann
    • 2
    • 3
  • Kenneth A. Sullivan
    • 4
  • E. Cabrina Campbell
    • 4
  1. 1.Department of PsychiatryVeterans Affairs Medical Center and the University of PennsylvaniaPhiladelphiaUSA
  2. 2.Department of Psychiatry and Behavioral ScienceThe University of Louisville School of MedicineLouisvilleUSA
  3. 3.Central Montgomery Mental Health and Mental Retardation CenterNorristownUSA
  4. 4.Department of PsychiatryVeterans Affairs Medical Center, University of Pennsylvania School of MedicinePhiladelphiaUSA

Personalised recommendations